作者
Maggie Li, Evan J Beck, Oliver Laeyendecker, Yolanda Eby, Aaron AR Tobian, Patrizio Caturegli, Camille Wouters, Gregory R Chiklis, William Block, Robert O McKie, Michael J Joyner, Timothy D Wiltshire, Allan B Dietz, Thomas J Gniadek, Arell J Shapiro, Anusha Yarava, Karen Lane, Daniel F Hanley, Evan M Bloch, Shmuel Shoham, Edward R Cachay, Barry R Meisenberg, Moises A Huaman, Yuriko Fukuta, Bela Patel, Sonya L Heath, Adam C Levine, James H Paxton, Shweta Anjan, Jonathan M Gerber, Kelly A Gebo, Arturo Casadevall, Andrew Pekosz, David J Sullivan
发表日期
2022/6/28
期刊
Blood advances
卷号
6
期号
12
页码范围
3678-3683
出版商
American Society of Hematology
简介
The ongoing evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants severely limits available effective monoclonal antibody therapies. Effective drugs are also supply limited. COVID-19 convalescent plasma (CCP) qualified for high antibody levels effectively reduces immunocompetent outpatient hospitalization. The Food and Drug Administration currently allows outpatient CCP for the immunosuppressed. Viral-specific antibody levels in CCP can range 10- to 100-fold between donors, unlike the uniform viral-specific monoclonal antibody dosing. Limited data are available on the efficacy of polyclonal CCP to neutralize variants. We examined 108 pre-δ/pre-ο donor units obtained before March 2021, 20 post-δ COVID-19/postvaccination units, and 1 pre-δ/pre-ο hyperimmunoglobulin preparation for variant-specific virus (vaccine-related isolate [WA-1], δ, and ο) neutralization …
学术搜索中的文章
M Li, EJ Beck, O Laeyendecker, Y Eby, AAR Tobian… - Blood advances, 2022